Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA's New Hypogonadism Guidance Focuses On Non-Testosterone Products

Executive Summary

Draft is intended to inform development of non-testosterone products such as aromatase inhibitors or estrogen receptor agonists.

Advertisement

Related Content

Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Disease-Specific Drug Development Guidances Coming From US FDA In 2018
Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte
Recent And Upcoming FDA Advisory Committee Meetings
Mereo On The Move With Strong COPD Data And US Listing Plan
Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures
Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene
Mereo BioPharma sets up shop with Novartis spin-offs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel